Sufentanil sublingual - AcelRx

Drug Profile

Sufentanil sublingual - AcelRx

Alternative Names: ARX-01; ARX-02; ARX-04; ARX-F01; ARX-F02; DSUVIA™; Sublingual sufentanil; Sublingual sufentanil - NanoTab; Sufentanil sublingual; Sufentanil sublingual microtablet; Sufentanil sublingual tablet system; Zalviso

Latest Information Update: 11 Jan 2017

Price : $50

At a glance

  • Originator AcelRx Pharmaceuticals
  • Developer AcelRx Pharmaceuticals; Grunenthal
  • Class Amides; General anaesthetics; Opioid analgesics; Piperidines; Small molecules; Thiophenes
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Postoperative pain
  • Preregistration Acute pain
  • Suspended Cancer pain

Most Recent Events

  • 08 Jan 2017 AcelRx Pharmaceuticals announces intention to submit MAA to EMA under the Centralised Procedure in 2017
  • 13 Dec 2016 Preregistration for Acute pain in USA (Sublingual)
  • 13 Dec 2016 Sufentanil sublingual is still awaiting regulatory approval in USA for Post-operative pain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top